The AI-powered Heuron ICH software reportedly has an 86 percent sensitivity rate for diagnosing intracranial hemorrhage on computed tomography (CT) scans.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Heuron ICH, an artificial intelligence (AI)-enabled software that may facilitate timely detection and triage of intracranial hemorrhages.
Through interpretation of non-contrast computed tomography (CT) scans, Heuron ICH offers an 86 percent sensitivity rate and an 88 percent specificity rate for intracranial hemorrhage, according to Heuron, the developer of Heuron ICH.
For diagnosing intracranial hemorrhages on non-contrast CT, the newly FDA-cleared Heuron ICH offers an 86 percent sensitivity rate and an 88 percent specificity rate. (Images courtesy of Adobe Stock.)
Heuron maintained that Heuron ICH facilitates rapid detection of intracranial hemorrhages and can diagnose minute hemorrhages that may evade radiologist detection.
The company noted that Heuron ICH is Heuron’s fifth AI software to garner FDA clearance.
"Securing this product approval marks a significant milestone, facilitating our swift penetration into the U.S. market,” noted Donghoon Shin, the CEO of Heuron. “Our commitment extends beyond this achievement as we endeavor to expand our portfolio of FDA-approved medical solutions. We are dedicated to optimizing the utilization of Heuron's diverse offerings within U.S. clinical environments, particularly for emergency patient care."
Study Assesses Potential of Seven-Minute AI-Enhanced 3T MRI of the Shoulder
February 20th 2025Researchers found that the use of seven-minute threefold parallel imaging-accelerated deep learning 3T MRI had 89 percent sensitivity for supraspinatus-infraspinatus tendon tears and 93 percent sensitivity for superior labral tears.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.